Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Ipilimumab in Mucosal Melanoma: NCT06999980 Clinical Landscape Report 2026
15 October 2026
NCT06999980 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
DR-0202 in Ovarian Cancer: NCT06999187 Clinical Landscape Report 2026
15 October 2026
NCT06999187 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Locally Advanced Melanoma: NCT07004335 Clinical Landscape Report 2026
15 October 2026
NCT07004335 clinical landscape for Locally Advanced Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MBS-303 in Glomerular disease: NCT07000292 Clinical Landscape Report 2026
15 October 2026
NCT07000292 clinical landscape for Glomerular disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Volrustomig in Renal Cell Carcinoma: NCT07000149 Clinical Landscape Report 2026
15 October 2026
NCT07000149 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dual-targeting BCMA-CD19 CAR-T cell(Beijing GoBroad Hospital) in Multiple Myeloma: NCT07003555 Clinical Landscape Report 2026
15 October 2026
NCT07003555 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07007312 Clinical Landscape Report 2026
15 October 2026
NCT07007312 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Budoprutug in Systemic Lupus Erythematosus: NCT07011043 Clinical Landscape Report 2026
15 October 2026
NCT07011043 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dual-targeting BCMA-GPRC5D CAR-T cell(Beijing GoBroad Hospital) in Multiple Myeloma: NCT07003568 Clinical Landscape Report 2026
15 October 2026
NCT07003568 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Bortezomib in Acute Myeloid Leukemia: NCT07008638 Clinical Landscape Report 2026
15 October 2026
NCT07008638 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Hemangiosarcoma: NCT07007273 Clinical Landscape Report 2026
15 October 2026
NCT07007273 clinical landscape for Hemangiosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Belumosudil Mesilate in Acute Myeloid Leukemia: NCT07006506 Clinical Landscape Report 2026
15 October 2026
NCT07006506 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.